Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “New York”

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisRecruiting
NCT05828069Phase 2Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis · Refractory Langerhans Cell Histiocytosis
United States, Australia, Canada
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruiting
NCT04671667Phase 2Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Oral Cavity Squamous Cell Carcinoma
United States
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With CancerCompleted
NCT03223753Phase 3Updated Jul 24, 2026
Sponsor: Children's Oncology Group
Carcinoma In Situ · Hematopoietic and Lymphatic System Neoplasm · Malignant Solid Neoplasm
United States, Canada
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell ArteritisRecruiting
NCT07108387Phase 2Updated Jul 24, 2026
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Giant Cell Arteritis (GCA)
United States
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesRecruiting
NCT07177352Phase 3Updated Jul 24, 2026
Sponsor: Hoffmann-La Roche
Alzheimers Disease
United States, Argentina, Australia, Brazil, Canada +9 more
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting
NCT06124157Phase 2Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia
United States, Australia, Canada, Puerto Rico
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid TumorsRecruiting
NCT07460375Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: LigaChem Biosciences, Inc.
Advanced Solid Tumors
United States, Canada, South Korea
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Recruiting
NCT05139017Phase 2, Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
DLBCL · Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Brazil, Canada +21 more
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruiting
NCT04181060Phase 3Updated Jul 24, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IIIB Lung Cancer AJCC v8
United States
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityActive Not Recruiting
NCT07311850Phase 3Updated Jul 24, 2026
Sponsor: Pfizer
Obesity and Overweight
United States, Bulgaria, Canada, Czechia, Germany +5 more
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderRecruiting
NCT07644052Phase 3Updated Jul 24, 2026
Sponsor: PleoPharma, Inc.
Cannabis Withdrawal
United States
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery LesionsRecruiting
NCT06779630NAUpdated Jul 24, 2026
Sponsor: Teleflex
Coronary Artery Disease
United States, Austria, France, Germany, Poland +1 more
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruiting
NCT07213674Phase 3Updated Jul 24, 2026
Sponsor: Amgen
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Austria, Belgium, Canada +13 more
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruiting
NCT04570423Phase 2Updated Jul 24, 2026
Sponsor: Spectrum Pharmaceuticals, Inc
Solid Tumors · Lymphoma
United States
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionActive Not Recruiting
NCT05968430Phase 3Updated Jul 24, 2026
Sponsor: Mineralys Therapeutics Inc.
Hypertension
United States, Australia, Bulgaria, Canada, France +8 more
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Recruiting
NCT07060807Phase 3Updated Jul 23, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Brazil, Canada +21 more
A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisRecruiting
NCT06072482Phase 4Updated Jul 23, 2026
Sponsor: Amgen
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
United States, Czechia, Denmark, Greece, Hungary +2 more
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive Not Recruiting
NCT05100862Phase 3Updated Jul 23, 2026
Sponsor: BeOne Medicines
Relapsed/Refractory Follicular Lymphoma · Marginal Zone Lymphoma
United States, Argentina, Australia, Austria, Belgium +23 more
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07213973Phase 2Updated Jul 23, 2026
Sponsor: Incyte Corporation
Hidradenitis Suppurativa (HS)
United States, Canada
Neonatal Phase 1 Valacyclovir StudyCompleted
NCT05468619Phase 1Updated Jul 23, 2026
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Simplex
United States
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid LeukemiaCompleted
NCT03836209Phase 2Updated Jul 23, 2026
Sponsor: PrECOG, LLC.
Acute Myeloid Leukemia
United States
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive Not Recruiting
NCT05554328Phase 2Updated Jul 23, 2026
Sponsor: National Cancer Institute (NCI)
Recurrent Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
United States, Puerto Rico
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruiting
NCT05675410Phase 3Updated Jul 23, 2026
Sponsor: National Cancer Institute (NCI)
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
United States, Canada, Puerto Rico
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionNot Yet Recruiting
NCT07540988Phase 3Updated Jul 23, 2026
Sponsor: Boehringer Ingelheim
Interstitial Lung Diseases
United States, Argentina, Austria, Belgium, Brazil +13 more
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryActive Not Recruiting
NCT05111574Phase 2Updated Jul 23, 2026
Sponsor: National Cancer Institute (NCI)
Anal Melanoma · Bladder Melanoma · Cervical Melanoma · Esophageal Melanoma
United States, Canada

Previous page Next page